Verinurad
Sponsors
AstraZeneca
Conditions
Asymptomatic HyperuricemiaChronic Kidney DiseaseHealthy Volunteers (Intended Indication: Chronic Kidney Disease)Heart Failure With Preserved Ejection Fraction (HFpEF)
Phase 1
A Study to Assess the Safety and Pharmacokinetics of Verinurad and Allopurinol in Asian and Chinese Subjects
CompletedNCT03836599
Start: 2019-01-16End: 2019-04-26Updated: 2019-05-13
A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart
CompletedNCT04256629
Start: 2020-03-03End: 2020-08-21Updated: 2022-01-31
Pharmacokinetics of Verinurad and Allopurinol in Combination With Cyclosporine and Rifampicin in Healthy Volunteers
CompletedNCT04532918
Start: 2020-09-10End: 2020-11-23Updated: 2023-03-27
Phase 2
A Study to Assess the Effect of Intensive Uric Acid (UA) Lowering Therapy With RDEA3170, Febuxostat, Dapagliflozin on Urinary Excretion of UA
CompletedNCT03316131
Start: 2017-10-25End: 2018-07-19Updated: 2019-08-28
A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
CompletedNCT03990363
Start: 2019-07-23End: 2021-11-22Updated: 2023-03-02
Study of Verinurad in Heart Failure With Preserved Ejection Fraction
CompletedNCT04327024
Start: 2020-05-19End: 2022-04-29Updated: 2023-06-29